CD19-CAR T cells after donor transplant to prevent relapse in adults with B-ALL
Official title: CD45RA-DEPLETED CD19-CAR T CELL CONSOLIDATION AFTER TCR alphabeta+ T CELL-DEPLETED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY CD19+ ALL AND LYMPHOMA
Funded at St. Jude Children's Research Hospital · NIH-11434386 · Data updated 2026-11-12
This study tests a new way to prevent relapse in adults with B-cell ALL by combining a donor bone marrow transplant with a special CAR T cell treatment, aiming to reduce relapse and avoid total body irradiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | July 23, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $737,023 |
| NIH project number | 1R01CA318641-01 |
| Project ID | NIH-11434386 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21 years and older) with high-risk B-ALL who are candidates for allogeneic hematopoietic cell transplantation and related donor-derived CAR T cell therapy.
✕Less likely to help
Patients not undergoing allo-HCT or those without eligible donor-derived CAR T cell options may not benefit from this trial.
What this research studies
Patients who have had an allogeneic stem cell transplant for high-risk B-cell ALL may benefit from adding donor-derived CD19-CAR(T Mem) T cells after TCRαβ-depleted grafts to reduce relapse and avoid radiation. The approach uses a cautious graft engineering strategy to limit graft-versus-host disease while enhancing anti-leukemia effects. The trial integrates transplant and CAR T cell therapy to create a supportive, relapse-sparing immune environment. Recruitment would target adults with relapsed or refractory B-ALL who are eligible for allo-HCT with TBI-free conditioning plans.
Why it matters
Potential benefit: If successful, the approach could lower relapse rates and reduce reliance on radiation in transplantation for B-ALL, improving survival and quality of life.
How similar studies have gone: Early translational work supports combining transplant and CAR T cell strategies to reduce relapse, with ongoing research exploring safety and GVHD control.
Where this research is happening
-
St. Jude Children's Research Hospital
Memphis, United States Active
Researchers
- Principal investigator: Naik, Swati — St. Jude Children's Research Hospital
- Study coordinator: Naik, Swati
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.